Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov 24:4:7182.
doi: 10.1038/srep07182.

Efficacy of intra-cervical misoprostol in the management of early pregnancy failure

Abdulrahim A Rouzi  1 , Nisma Almansouri  1 , Nora Sahly  1 , Nawal Alsenani  1 , Hussam Abed  1 , Khalid Darhouse  1 , Nabil Bondagji  1
Affiliations

Efficacy of intra-cervical misoprostol in the management of early pregnancy failure

Abdulrahim A Rouzi et al. Sci Rep. .

Abstract

The aim of this prospective study was to assess the efficacy of intra-cervical misoprostol in the management of early pregnancy failure. Twenty women with early pregnancy failure received intra-cervical misoprostol via an endometrial sampling cannula. The first dose was 50 μg of misoprostol dissolved in 5 ml of normal saline. The administration was repeated after 12 h if there was no vaginal bleeding or pain. Nine (45%) women received 1 dose and 11 (55%) women received 2 doses of intra-cervical misoprostol. Abortion within 24 h occurred in 16 (80%) women, and complete abortion was achieved in 14 (70%) cases. Two women with incomplete abortion were managed with 600 μg of misoprostol orally (1 case) and surgical intervention (1 case). The mean time interval between the first dose and the abortion was 10.6 ± 6.3 h. Two women did not respond within 24 h of treatment initiation, 1 woman withdrew consent after the first treatment, and 1 woman developed heavy vaginal bleeding after the first dose and underwent surgical management. Intra-cervical misoprostol is a promising method of medical treatment of early pregnancy failure. Further randomized clinical trials are needed to validate its safety and efficacy.

PubMed Disclaimer

References

    1. Regan L. & Rai R. Epidemiology and the medical causes of miscarriage. Best Pract Res Cl Ob. 14, 839–54 (2000). - PubMed
    1. Stockheim D., Machtinger R. & Wiser A. A randomized prospective study of misoprostol or mifepristone followed by misoprostol when needed for the treatment of women with early pregnancy failure. Fertil Steril. 86, 956–60 (2006). - PubMed
    1. American College of Obstetricians and Gynecologists. Medical management of first-trimester abortion. ACOG practice bulletin no. 143. Obstet Gynecol. 123, 676–92 (2014). - PubMed
    1. World Health Organization, Department of Reproductive Health and Research. Safe abortion: technical and policy guidance for health systems, 2012. http://www.who.int/reproductivehealth/publications/unsafe_abortion/97892.... Date of access 23/10/2014.
    1. Gronlund A. et al. Management of missed abortion: comparison of medical treatment with either mifepristone plus misoprostol or misoprostol alone with surgical evacuation. A multi-center trial in Copenhagen county, Denmark. Acta Obstet Gynecol Scand. 81, 1060–65 (2002). - PubMed

Substances